{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG000","lowerLimit":"48.0","upperLimit":"NA","value":"66.0"},{"comment":"The median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died.","groupId":"OG001","lowerLimit":"55.0","upperLimit":"NA","value":"NA"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG002","lowerLimit":"64.0","upperLimit":"NA","value":"116.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG003","lowerLimit":"76.0","upperLimit":"NA","value":"88.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG004","lowerLimit":"29.0","upperLimit":"NA","value":"57.0"},{"comment":"The median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died.","groupId":"OG005","lowerLimit":"100.0","upperLimit":"NA","value":"NA"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG006","lowerLimit":"52.0","upperLimit":"NA","value":"98.0"},{"comment":"The median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died.","groupId":"OG007","lowerLimit":"97.0","upperLimit":"NA","value":"NA"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG008","lowerLimit":"53.0","upperLimit":"NA","value":"134.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG009","lowerLimit":"56.0","upperLimit":"NA","value":"128.0"},{"comment":"The median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died.","groupId":"OG010","lowerLimit":"46.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"6"}],"units":"Participants"}],"description":"According to mRECIST 1.1, PFS was defined as the length of time between the Baseline visit (Day 1) and the earlier of the participant's death or the first confirmed assessment of PD, as determined by investigator assessment of objective radiographic disease assessments. The response of target lesions was evaluated from the percentage change in the sum of the diameters of the viable portions (portions enhanced during the arterial phase).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received INCAGN01876 1.0 milligrams per kilogram (mg/kg) administered intravenously (IV) every 2 weeks (Q2W) in combination with nivolumab 240 mg administered IV Q2W.INCAGN01876 combined with nivolumab.","id":"OG000","title":"Phase 1 Group A: INCAGN01876 1.0 mg/kg Q2W + Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 3.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG001","title":"Phase 1 Group A: INCAGN01876 3.0 mg/kg Q2W + Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 5.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG002","title":"Phase 1 Group A: INCAGN01876 5.0 mg/kg Q2W + Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 10.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG003","title":"Phase 1 Group A: INCAGN01876 10.0 mg/kg Q2W + Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 1.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by nivolumab 240 mg administered IV Q2W starting at Cycle 3.","id":"OG004","title":"Phase 1 Group B: INCAGN01876 1.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 3.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by nivolumab 240 mg administered IV Q2W starting at Cycle 3.","id":"OG005","title":"Phase 1 Group B: INCAGN01876 3.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 5.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by nivolumab 240 mg administered IV Q2W starting at Cycle 3.","id":"OG006","title":"Phase 1 Group B: INCAGN01876 5.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 1.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV every 6 weeks (Q6W).","id":"OG007","title":"Phase 1 Group C: INCAGN01876 1.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W"},{"description":"Participants received INCAGN01876 3.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.","id":"OG008","title":"Phase 1 Group C: INCAGN01876 3.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W"},{"description":"Participants received INCAGN01876 5.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.","id":"OG009","title":"Phase 1 Group C: INCAGN01876 5.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W"},{"description":"Participants received INCAGN01876 1.0 mg/kg administered IV Q2W in combination with nivolumab 3 mg/kg administered IV Q2W and ipilimumab 1 mg/kg administered IV Q6W.","id":"OG010","title":"Phase 1 Group D: INCAGN01876 + Nivolumab + Ipilimumab"}],"paramType":"MEDIAN","populationDescription":"Phase 1 FAS. Median survival time was estimated using the Kaplan-Meier method. The confidence interval for median survival time was calculated using the method of Brookmeyer and Crowley.","reportingStatus":"POSTED","timeFrame":"up to approximately 44.7 months","title":"Phase 1: PFS Per mRECIST v1.1","type":"SECONDARY","unitOfMeasure":"Days"}